Meet Dicronis, the Accelerator startup that will improve lives of cancer patients

Overview

Patrizia Marschalkova, co-founder and CEO of Dicronis , the swiss startup that joined our Accelerator aims to improve lives of cancer patients.

Publish Date

24 FEB 2019

Patrizia Marschalkova, co-founder and CEO of Dicronis , the swiss startup that joined our Accelerator aims to improve lives of cancer patients.

The team developed the very first lymphatic activity tracker that will help prevent lymphedema from occurring. The startup focuses on developing innovative diagnostic products for diseases with high unmet medical needs.

The first product in their pipeline, Lymphit, allows for the tracking of the lymphatic function in an easy-to-use, painless, home-based, and highly-scalable manner. Using microneedle patches, Dicronis delivers a fluorescent agent to the patient’s skin and measures its uptake through the lymphatics via a wearable detector. In this way, the best therapy strategy for the patient is identified.

First of all the team plans to address the early diagnosis and efficient monitoring of lymphedema, a chronic and progressive complication of some cancer therapies.


Enjoyed the read?

To keep up to date with all new happenings at our Innovation Center, click here to subscribe to our e-mail service.

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement